Liisa Ann Bayko
CIK: 0002145720
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
KLRS
Kalaris Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About Bayko Liisa Ann
Bayko Liisa Ann (SEC CIK 0002145720) files insider reports with the SEC as Chief Financial Officer of Kalaris Therapeutics, Inc. (KLRS).
Signal8 holds 2 ownership filings by Bayko Liisa Ann (1 Form 3, 1 Form 4), filed on Jul 20, 2026. Those filings report 1 transaction, the latest on Jul 20, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bayko Liisa Ann's filings is in BERKELEY HEIGHTS, NJ.
Recent filings by Bayko Liisa Ann
- Jul 20, 2026: Grant or award of KLRS derivative securities (Form 4, code A).
Other insiders filing for Kalaris Therapeutics, Inc. (KLRS)
- Vandekop Amy O'Leary, VP, Corporate Controller
- KEATING LAURIE, Director
- Jovan-Embiricos Morana, Director
- Ferrara Napoleone, Director
- Hallal David, Director
- AKKARAJU SRINIVAS, Director